Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02264418
Other study ID # 3113001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 18, 2014
Est. completion date May 2019

Study information

Verified date January 2020
Source Orion Corporation, Orion Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this first-in-human study is to evaluate the safety and tolerability of escalating doses of ODM-203 in subjects with advanced solid tumours and to determine the maximum tolerated dose and dose limiting toxicities.


Description:

The safety profile of ODM-203 will be explored together with the pharmacokinetics, pharmacodynamics and tumour response to treatment with ODM-203 to recommend the dosing regimen for further clinical studies. The pharmacokinetic properties of ODM 203 will be evaluated after single and multiple dose administrations at different dose levels


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date May 2019
Est. primary completion date May 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Written informed consent

- Male and female subjects over 18 years of age

- Subjects with histologically or cytologically confirmed locally advanced or metastatic tumours. Subjects in Part 2 to have a tumour/genetic aberration.

- Availability of tumour sample for genetic analysis

- Adequate haemopoietic, hepatic and renal function

- Eastern Cooperative Oncology Group performance status of 0 to 1

- Serum mineral levels phosphate: 2.5 mg/dl; calcium: 8.8 mg/dl; magnesium: 1.2 mg/dl; potassium: 11.7 mg/dl; sodium: 299mg/dl.

- Recovery from reversible adverse events of previous systemic anti-cancer therapies to baseline or grade 1 with the exception of alopecia;stable neuropathy of grade 2 induced by previous cancer treatment

- Life expectancy of 12 weeks or more

Exclusion Criteria:

- Any prior anti VEGFR/FGFR treatment related AE that in the judgement of the investigator is considered severe/life threatening

- Subjects receiving warfarin

- Active central nervous system metastases not controlled by prior surgery/radiotherapy and/or low dose steroids for 4 weeks or more

- Subjects with current evidence of endocrine alteration of calcium-phosphate homeostasis

- Concomitant therapies known to increase serum phosphorus and/or calcium levels that cannot be discontinued or switched to a different therapy are not permitted within 14 days before the first dose of ODM-203.

- Significant cardiovascular conditions/circumstances as follows:

- a active or unstable cardio/cerebro-vascular disease

- b Uncontrolled hypertension (systolic blood pressure = 150mmHg and/or diastolic blood pressure = 90mg Hg with optimised antihypertensive therapy.

- c history of severe arrhythmia, familial arrhythmia, conduction abnormality or congenital long QT syndrome

- dConcomitant therapies known to prolong the QT interval and associated with a risk of Torsades de Pointes are not permitted within 7 days before the first dose of ODM 203

- e Repeatable prolongation of QTcF interval = 450 msec or any clinically significant abnormality in the ECG at screening in 2 out of 3 recordings

- f Left ventricular ejection fraction <50% at screening

- Subjects who received systemic anticancer treatment prior to the first dose of ODM-203 within the following timeframes: less than 28 days since the last dose of antineoplastic therapy and/or 28 days of wide field radiotherapy or 14 days of limited field radiation for palliation

- Major surgery or serious infection within 21 days of the first dose of ODM-203

- Known gastrointestinal disease or a procedure that may affect absorption of ODM 203

- Serious concurrent medical condition or psychiatric illness

- History and/or current evidence of ectopic mineralisation/calcification

- Known active or past history of other primary malignancy

- Female of child bearing potential

- Female of child bearing potential or male subject with a female partner of child bearing potential who does not agree to use effective contraception during the study and for 3 months after the last dose of ODM 203

- Known hypersensitivity to the study treatment excipients

- Any condition which in the opinion of the investigator would impair the subject's ability to comply with the study procedures

- Participation in another interventional clinical trial/ concurrent treatment with any investigational drug within 4 weeks prior to the start of treatment with ODM 203

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ODM 203
ODM 203
ODM 203
ODM 203

Locations

Country Name City State
Denmark Finsen Centre Copenhagen
Finland Helsinki University Central Hospital, Department of Oncology Helsinki
France Institut Bergonie Bordeaux
France Gustave Roussy Oncology Institute Villejuif
Italy European Institute of Oncology Milan
Spain Vall d'Hebron University Hospital Barcelona
United Kingdom Sarah cannon Research Institute London
United Kingdom UCL Cancer Institute London

Sponsors (1)

Lead Sponsor Collaborator
Orion Corporation, Orion Pharma

Countries where clinical trial is conducted

Denmark,  Finland,  France,  Italy,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of adverse events Number of adverse event counts From the date of informed consent to the date of the end of study visit estimated to be 6 months
Secondary Frequency of responders to Response evaluation criteria in solid tumours (RECIST) The frequency of responders according to RECIST will be evaluated by dose level. Subjects will be followed for the duration of time in the study, expected to be an average of 6 months
Secondary Eastern Cooperative Oncology Group (ECOG) Performance status The ECOG performance status and the change from baseline will be reported by dose level. Subjects will be followed for the duration of time in the study, expected to be an average of 6 months
Secondary Area under the plasma concentration curve (AUC) Area under the plasma concentration curve (AUC) of ODM-203 will be measured to evaluate the relationship between ODM-203 dose, plasma exposure, pharmacodynamics and safety 0 to 24hours post dose Day 1 and Day 15
Secondary Peak plasma concentration (Cmax) Peak plasma concentration (Cmax) of ODM-203 will be measured to evaluate the relationship between ODM-203 dose, plasma exposure, pharmacodynamics and safety After first dose administration to 24 hours Day 1 and Day 15
See also
  Status Clinical Trial Phase
Completed NCT03315091 - Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours Phase 1
Completed NCT01921140 - To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours Phase 1
Completed NCT00732420 - Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors Phase 1
Recruiting NCT03572192 - Tissue Collection Framework To Improve Outcomes In Solid Tumours
Completed NCT02360345 - Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly Phase 1
Completed NCT02093351 - To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer Phase 1
Completed NCT01956669 - Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Phase 2
Recruiting NCT02215850 - Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours Phase 1
Recruiting NCT02263950 - A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT01931761 - Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers Phase 1
Completed NCT01900028 - To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours Phase 1
Completed NCT00136578 - Ispinesib In Combination With Carboplatin In Patients With Solid Tumors Phase 1
Completed NCT01184274 - A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia Phase 1
Withdrawn NCT03266159 - A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors Phase 2
Active, not recruiting NCT01894256 - Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function Phase 1
Completed NCT01974349 - To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Phase 1
Completed NCT02923947 - Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment Phase 1
Completed NCT02056392 - To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers Phase 1
Completed NCT02063204 - To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects Phase 1
Completed NCT00742131 - A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors Phase 1